Net margin is calculated as Net Income divided by its Revenue. Novavax's Net Income for the
three
months ended in Mar. 2026 was MXN-171 Mil. Novavax's Revenue for the
three
months ended in Mar. 2026 was MXN2,516 Mil. Therefore, Novavax's net margin for the quarter that ended in Mar. 2026 was -6.80%.
The historical rank and industry rank for Novavax's Net Margin % or its related term are showing as below:
MEX:NVAX'
s Net Margin % Range Over the Past 10 Years
Min: -1868.23 Med: -564.14 Max: 39.19
Current: -14.73
MEX:NVAX's Net Margin % is ranked better than 64.13% of 945
companies
in the Biotechnology industry
Industry Median: -89.33
vs MEX:NVAX: -14.73
Novavax (MEX:NVAX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Novavax Net Margin % Related Terms
Novavax Net Margin % Historical Data
* Premium members only.
The historical data trend for Novavax's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVAX vs QURE, HRMY, IOVA: Net Margin % Comparison
For the Biotechnology subindustry, Novavax's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's Net Margin % distribution charts can be found below:
* The bar in red indicates where Novavax's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax (MEX:NVAX) has a Net Margin % of -6.80% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Novavax and its competitors. According to the industry distribution chart, Novavax ranks #339 out of 945 companies in the Biotechnology industry, placing it in the top 35.9%.
Is Novavax's Net Margin % too high?
Novavax's current Net Margin % is -6.80%. Based on the distribution chart, Novavax ranks #339 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Net Margin % compare to QURE and HRMY?
According to the Biotechnology industry distribution chart, Novavax ranks #339 out of 945 companies for Net Margin %. This puts Novavax in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Novavax and its competitors. Novavax's current Net Margin % is -6.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN68.69, compared to a current price of MXN156.00 — trading 127.1% above its estimated fair value. The current Net Margin % is -6.80%. Novavax's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Net Margin % is -6.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (MEX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of MXN156.00 is trading 127.1% above its estimated GF Value™ of MXN68.69.
GuruFocus considers Novavax to be Significantly Overvalued.
Key valuation signals for MEX:NVAX:
Net Margin %: -6.80%
GF Value™: MXN68.69 vs. price of MXN156.00 (127.1% above fair value)
No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score
Get the complete analysis for MEX:NVAX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVAX has been successfully added to your 
